BETHESDA, MD — The Consumer Healthcare Products Association (CHPA) has named W. Greg Collier, Ph.D., as the recipient of its 2025 William Cooley Regulatory & Scientific Affairs Career Achievement Award, recognizing more than three decades of leadership and contributions to the consumer healthcare products industry.
The award, presented annually at CHPA’s Regulatory, Scientific & Quality (RSQ) Conference, honors individuals who have advanced self-care and public health through enduring achievements in regulatory and scientific affairs. It is named after Dr. William Cooley, whose 40-year career left a lasting impact on the field.
Dr. Collier’s 34-year career includes 25 years directing global regulatory strategies at Procter & Gamble (P&G) for leading brands such as Vicks, Metamucil, Prilosec, Align, Crest, and Oral-B. He played key roles in guiding acquisitions, including Gillette Oral-B, a partnership with Teva Pharmaceuticals, and the integration of Merck Consumer Health. Since retiring from P&G in 2021, Collier has continued to shape regulatory policy as a consultant, serving four years on FDA’s Nonprescription Drugs Advisory Committee and helping to negotiate and secure the landmark OTC Monograph User Fee Act (OMUFA).
“Dr. Collier’s decades of dedication, vision, and leadership embody the spirit of this award,” said CHPA President and CEO Scott Melville. “Greg is a strong and collaborative leader, whose success in diverse roles at P&G were coupled with a dedication to industry collaboration through his work at CHPA. As a former chair of the CHPA Regulatory Affairs & Scientific Affairs Committee, Greg also served as a chief industry negotiator on the team that helped secure the historic 2020 OTC Monograph User Fee Act, a legacy achievement that will help consumer healthcare for decades ahead. From his early work at Procter & Gamble to his essential role in shaping OMUFA, Dr. Collier’s work has strengthened the regulatory framework that supports innovation and ensures today’s consumers have access to safe, effective OTC medicines. CHPA thanks Dr. Collier for his commitment to public health and regulatory excellence and congratulates him on this prestigious honor.”
Collier was honored during CHPA’s RSQ Conference on September 9 at the Bethesda North Marriott Hotel and Conference Center. The award was presented by Glen Murphy, Senior Director of Regulatory Affairs at Kenvue and chair of CHPA’s 2025 RSQ Conference Planning Committee.
This year’s RSQ Conference brought together more than 255 participants and 55 speakers from healthcare, government, and academia, including FDA leaders across the Human Foods Program, Center for Devices and Radiological Health, Center for Drug Evaluation and Research, and Office of Dietary Supplement Programs.
Founded in 1881, CHPA is the national trade association representing leading manufacturers and marketers of over-the-counter medicines, dietary supplements, and consumer medical devices, with a mission to expand safe, effective self-care for all Americans.
